At a glance
ClinicalIndex Comparison RecordN/ACompleted· 66 enrolled
Drug / intervention
Reveal® DX or Reveal® XT Insertable Cardiac Monitordevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Reveal® In-Office Implants Study
In Brief
An observational study evaluating Reveal® DX or Reveal® XT Insertable Cardiac Monitor for Arrhythmias, Cardiac. Completed, enrolled 66 participants across 9 sites.
Detailed Summary
The purpose of this study is to gather evidence about the safety and feasibility of performing the implant procedure for the Reveal Insertable Cardiac Monitor (ICM) in an office or clinic setting rather than the traditional hospital operating room, cardiac catheterization or electrophysiology (EP) laboratory setting.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsArrhythmias, Cardiac
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJul 2010
Enrollment StartAug 2010
Primary CompletionMay 2011
TodayJul 2026
First PostedJul 23, 2010
Enrollment StartAug 1, 2010
Primary CompletionMay 1, 2011
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 15.9 years ago
Interventions
Reveal® DX or Reveal® XT Insertable Cardiac Monitordevice
Reveal® DX and Reveal® XT Insertable Cardiac Monitors are implantable patient-activated and automatically-activated monitoring systems that record subcutaneous ECG.